MAPT and Alzheimer disease: Although larger than many of the published genome-wide studies of amyloid-positron emission tomography and other Alzheimer’s disease endophenotypes, our GWAS of tau-positron emission tomography included a relatively modest sample size compared to non-biomarker-based studies.